A recent study shows that a derivative of tubercidin, a natural product from Streptomyces, selectively inhibits influenza A and B viruses by targeting the host RNA methyltransferase MTr1, thus preventing viral "cap snatching." This approach may lead to the development of novel drugs that target viral host dependency factors and are less likely to induce viral resistance. Influenza remains a global health threat, and there is a need for new therapeutic strategies against the virus. Currently available drugs targeting the viral neuraminidase or ion channel have limited efficacy due to rapid viral evolution and resistance. Novel therapeutics that target cellular factors critical for viral replication are less prone to resistance. The study highlights the importance of understanding the viral replication process and host-virus interactions in developing effective antiviral strategies.